K
Karla V. Ballman
Researcher at Cornell University
Publications - 390
Citations - 34158
Karla V. Ballman is an academic researcher from Cornell University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 78, co-authored 353 publications receiving 29127 citations. Previous affiliations of Karla V. Ballman include University of South Florida & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial
Judy C. Boughey,Linda M. McCall,Karla V. Ballman,Elizabeth A. Mittendorf,Gretchen M. Ahrendt,Lee G. Wilke,Bret Taback,A. Marilyn Leitch,Teresa S. Flippo-Morton,Kelly K. Hunt +9 more
TL;DR: Patients with triple-negative and HER2-positive breast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherapy, and patients with these subtypes are most likely to be candidates for less invasive surgical approaches after chemotherapy.
Journal ArticleDOI
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
Christopher E. Pelloski,Karla V. Ballman,Alfred F. Furth,Li Zhang,E. Lin,Erik P. Sulman,Krishna P. Bhat,J. Matthew McDonald,W. K. Alfred Yung,Howard Colman,Shiao Y. Woo,Amy B. Heimberger,Dima Suki,Michael D. Prados,Susan M. Chang,Fred G. Barker,Jan C. Buckner,C. David James,Kenneth Aldape +18 more
TL;DR: Established prognostic factors in GBM were not predictive of outcome in the EGFRvIII-positive subset, although this requires confirmation in independent data sets.
Journal ArticleDOI
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
Reshma Jagsi,Manjeet Chadha,Janaki Moni,Janaki Moni,Karla V. Ballman,Fran Laurie,Thomas A. Buchholz,Armando E. Giuliano,Bruce G. Haffty +8 more
TL;DR: Most patients treated in Z0011 received tangential RT alone, and some received no RT at all; further research is necessary to determine the optimal RT approach in patients with low-volume axillary disease treated with SLND alone.
Journal ArticleDOI
Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population
R. Jeffrey Karnes,Eric J. Bergstralh,Elai Davicioni,Mercedeh Ghadessi,Christine Buerki,Anirban P. Mitra,Anamaria Crisan,Nicholas Erho,Ismael A. Vergara,Lucia L. Lam,Rachel Carlson,Darby J. S. Thompson,Zaid Haddad,Benedikt Zimmermann,Thomas Sierocinski,Timothy J. Triche,Thomas M. Kollmeyer,Karla V. Ballman,Peter C. Black,George G. Klee,Robert B. Jenkins +20 more
TL;DR: Results indicate that genomic information from the primary tumor can identify patients with adverse pathological features who are most at risk for metastasis and potentially lethal prostate cancer.
Journal ArticleDOI
A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases.
Brian P. O'Neill,Nancy Iturria,Michael J. Link,Bruce E. Pollock,Karla V. Ballman,Judith R. O'Fallon +5 more
TL;DR: The need for a Phase III study comparing these two techniques appears to be supported by the data from this study, and a significant prognostic factor for survival was a performance score of 0 or 1.